Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Código QR

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Abstract Background Visceral metastases account for 48–67% of metastatic breast cancer (MBC) patients and presage a worse overall survival. Previous study suggested potential effect of nab-paclitaxel on patients with visceral metastases subgroups. This phase II trial was conducted to explore the eff...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Metastatic breast Cancer Chemotherapy Nab-paclitaxel Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8b66bb85b7d0499482ca3c9ffebd7fdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017)

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
por: Bryce D. Beutler, et al.
Publicado: (2015)

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin F, et al.
Publicado: (2016)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)

Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
por: Michael Pigula, et al.
Publicado: (2021)

Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer
por: Bochao Zhao, et al.
Publicado: (2019)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Yannan Zhao, et al.
Publicado: (2018)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Ammar Sukari, et al.
Publicado: (2015)

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo
por: Wang N, et al.
Publicado: (2017)

Heptamethine Cyanine Dye MHI-148-Mediated Drug Delivery System to Enhance the Anticancer Efficiency of Paclitaxel
por: Raveendran A, et al.
Publicado: (2021)

Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration
por: Dian LH, et al.
Publicado: (2018)

Targeted paclitaxel‐octreotide conjugates inhibited the growth of paclitaxel‐resistant human non‐small cell lung cancer A549 cells in vitro
por: Yanguo Liu, et al.
Publicado: (2021)

Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis
por: Hu Y, et al.
Publicado: (2021)

Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment
por: Zhong Y, et al.
Publicado: (2019)

Association of radiation dose intensity with overall survival in patients with distant metastases
por: Johnny Kao, et al.
Publicado: (2021)

Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer
por: Hu B, et al.
Publicado: (2018)

Chronic chemotherapy with paclitaxel nanoparticles induced apoptosis in lung cancer in vitro and in vivo
por: Zhao X, et al.
Publicado: (2019)

Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity
por: Han B, et al.
Publicado: (2020)

Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells
por: Ting Huang, et al.
Publicado: (2021)

Wear Behavior of Friction Stir Processed NAB Alloys in Marine Environment
por: Vishnu Namboodiri V, et al.
Publicado: (2018)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: Ruben A. G. van Eerden, et al.
Publicado: (2021)

Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells
por: Xu W, et al.
Publicado: (2018)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Leisha A Emens, et al.
Publicado: (2021)

Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio
por: Marjorie Coimbra Roque, et al.
Publicado: (2021)

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
por: Jin M, et al.
Publicado: (2021)

Are we there yet? A machine learning architecture to predict organotropic metastases
por: Michael Skaro, et al.
Publicado: (2021)

Anticancer activity of paclitaxel-loaded keratin nanoparticles in two-dimensional and perfused three-dimensional breast cancer models
por: Foglietta F, et al.
Publicado: (2018)

Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer
por: Zhao MD, et al.
Publicado: (2019)

Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis
por: Huang Bo, et al.
Publicado: (2021)

Mechanisms, Diagnosis and Treatment of Bone Metastases
por: Jozef Ban, et al.
Publicado: (2021)

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
por: Wu M, et al.
Publicado: (2017)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Mateusz Malik, et al.
Publicado: (2021)

Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo
por: Xu MQ, et al.
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

SHORT-TERM RESULTS OF SIMULTANEOUS SURGERIES AT METASTATIC COLORECTAL CANCER
por: A. S. Zagaynov, et al.
Publicado: (2017)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li Y, et al.
Publicado: (2020)

Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis
por: Dara Brena, et al.
Publicado: (2022)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)